Sch 29482: Activity against susceptible and β-lactam resistant variants of Enterobacteriaceae

The comparative activity of cefamandole, cefoxitin, cefotaxime, moxalactam thienamycin and Sch 29482 (SCH) was studied on homologous pairs of susceptible and resistant variants obtained by a single event in the same bacteria achieved by: modification of PBPs, multicopy plasmid, gene amplification an...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 1982-02, Vol.9 (suppl-C), p.203-212
Main Authors: Chabbert, Y. A., Jaffé, A.
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - pharmacology
Bacterial Proteins
beta-Lactamases - metabolism
beta-Lactams - pharmacology
Carrier Proteins - metabolism
Drug Resistance, Microbial
Enterobacteriaceae - drug effects
Enterobacteriaceae - enzymology
Hexosyltransferases
Isoelectric Focusing
Lactams
Muramoylpentapeptide Carboxypeptidase
Mutation
Penicillin-Binding Proteins
Peptidyl Transferases
Plasmids
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The comparative activity of cefamandole, cefoxitin, cefotaxime, moxalactam thienamycin and Sch 29482 (SCH) was studied on homologous pairs of susceptible and resistant variants obtained by a single event in the same bacteria achieved by: modification of PBPs, multicopy plasmid, gene amplification and spontaneous susceptible variants. Resistance to all drugs of Serratia marcescens isolated from blood culture was related to modifications of PBPs. The introduction in Escherichia coli K12 of multicopy plasmids coding for TEM 1, SHV 1, OXA 3 β-lactamases did not change the 99 percent inhibitory concentration (IC99 of this strain for all drugs except cefamandole. Variants of Enterobacter cloacae, Citrobacter freundii hyperproducing β-lactamases of different isoelectric points were 100- to 1000-fold more resistant than their susceptible counterpart to cefamandole, cefoxitin, cefotaxime and moxalactam. In contrast the activity of penem derivatives, thienamycin and SCH, remained unchanged towards susceptible and resistant variants.
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/9.suppl_C.203